From the Food and Drug Administration.
Nightingale
S L
SL
D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000592:standards*; D004992:Ethics, Medical; D006801:Humans; D008327:Mammography / Q000592:standards*; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011786:Quality Control; D012106:Research / Q000592:standards*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator